Back to results
US 2019/0241619 A1Published application
Novel Promiscuous HPV16-Derived T Helper Epitopes for Immunotherapy
AssigneeDeutsches Krebsforschungszentrum Stiftung des Öffenttichen Rechts
InventorsAgnieszka Grabowska, Angelika Riemer
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel amino acid sequences of peptides derived from HPV16 that are able to promiscuously bind to MHC complexes of class II and shorter peptides contained in the promiscuously binding peptides that bind to MHC complexes of class I, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and T-cells, based on said epitopes.
Claims18
A peptide comprising a sequence selected from the group of SEQ ID NO:
- 7, and SEQ ID NOs:
- 32 to 42, or a variant of SEQ ID NO:
- 7, or any of SEQ ID NOs:
- 32 to 42, wherein said variant is 80% homologous to SEQ ID NO:
- 7, or any of SEQ ID NOs:
- 32 to 42, and wherein said peptide or parts thereof have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-II and/or class-I, and wherein said peptide has an overall length of between 8 and 50 amino acids.
3 more elements
Dependencies are inferred from the claim text.